The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
Open accessAbstract
BACKGROUND: Multiple sclerosis (MS) is an important problem both for people with the disease and for society. There is no cure, and alleviation of symptoms forms the cornerstone of care. Excessive fatigue that severely limits activity is experienced by at least two-thirds of the estimated 60,000 people with MS in the UK. OBJECTIVES: (1) To identify current treatments for fatigue in MS and their evidence-base. (2) To systematically review the evidence for those treatments that have been investigated in more than one rigorous study, in order to determine their effectiveness and cost-effectiveness. METHODS: The review was carried out in two stages: a formal scoping review (to assess the range of interventions used by people with MS), and a systematic review for treatments that had been identified as promising and that had been investigated in clinical trials (as identified in the scoping review). A systematic review of research on costs and cost-effectiveness of those interventions identified as promising was also performed. Electronic databases, including MEDLINE and EMBASE, were searched for the period 1991-June 1999 (scoping review) and 1966-December 1999 (systematic review). Reference lists from publications were also searched, and experts were contacted for any additional information not already identified. RESULTS: Interventions identified for the treatment of fatigue in MS (1) Behavioural advice. This is the main element of initial clinical management and no rigorous research of its effectiveness was identified. (2) Drugs (amantadine, pemoline, potassium-channel blockers and antidepressants). (3) Training, rehabilitation and devices (cooling vests and electromagnetic fields). (4) Alternative therapies (bee venom, cannabis, acupuncture/acupressure and yoga). Only two drugs, amantadine and pemoline, met the criteria for full systematic review. RESULTS - EFFECTIVENESS OF AMANTADINE: One parallel and three crossover trials were found, involving a total of 236 people with MS. All studies were open to bias. All studies showed a pattern in favour of amantadine compared with placebo, but there is considerable uncertainty about the validity and clinical significance of this finding. This pattern of benefit was considerably undermined when different assumptions were used in the sensitivity analysis. RESULTS - EFFECTIVENESS OF PEMOLINE: One parallel and one crossover trial were found involving a total of 126 people with MS. Both studies were open to bias. There was no overall tendency in favour of pemoline over placebo and an excess of reports of adverse effects with pemoline. RESULTS - HEALTH ECONOMIC ANALYSIS: The drug costs of amantadine and pemoline are modest (pound 200 and pound 80 per annum, respectively). No economic evaluations were identified in the systematic review, and available data were insufficient to allow modelling of cost-effectiveness in this rapid review. CONCLUSIONS: There is insufficient evidence to allow people with MS, clinicians or policy makers to make informed decisions on the appropriate use of the many treatments on offer. Only amantadine appears to have some proven ability to alleviate the fatigue in MS, though only a proportion of users will obtain benefit and then only some of these patients will benefit sufficiently to take the drug in the long term. CONCLUSIONS - RECOMMENDATIONS FOR RESEARCH: The frequency, severity and impact of fatigue, the poverty of available research, and the absence of any ongoing research, suggest that new research is an urgent priority. People with MS, clinicians and policy makers should work together to ensure that the evidence required is collected as quickly as possible by encouraging involvement in rigorous research. Research should not be restricted to the two drugs reviewed in depth in this report. All interventions identified in the scoping review (see above) should be considered, as should basic scientific research into the underlying mechanism of fatigue in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Krupp, L. B. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460115022 · Cited by 6,172
Development of a fatigue scale
Chalder, T., Berelowitz, G., Pawlikowska, T., Watts, L., Wessely, S., Wright, D., & Wallace, E. P. (1993) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(93)90081-p · Cited by 3,032
Clinical Trials: A Practical Approach.
Hill, I. D., & Pocock, S. J. (1984) · Biometrics · doi:10.2307/2531186 · Cited by 2,930
Measuring the Functional Impact of Fatigue: Initial Validation of the Fatigue Impact Scale
Fisk, J. D., Ritvo, P. G., Ross, L., Haase, D. A., Marrie, T. J., & Schlech, W. F. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.supplement_1.s79 · Cited by 1,541
The impact of fatigue on patients with multiple sclerosis
Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100048691 · Cited by 1,025
Krupp, L. B., Alvarez, L. A., LaRocca, N. G., & Scheinberg, L. C. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520280085020 · Cited by 997
Cross-Over Trials in Clinical Research
(1994) · Technometrics · doi:10.1080/00401706.1994.10485798 · Cited by 763
Impact of aerobic training on fitness and quality of life in multiple sclerosis
Petajan, J. H., Gappmaier, E., White, A. T., Spencer, M. K., Mino, L., & Hicks, R. W. (1996) · Annals of Neurology · doi:10.1002/ana.410390405 · Cited by 757
The measurement of fatigue: a new instrument
Schwartz, J. E., Jandorf, L., & Krupp, L. B. (1993) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(93)90104-n · Cited by 562
Symptomatic fatigue in multiple sclerosis.
Freal, J. E., Kraft, G. H., & Coryell, J. K. (1984) · PubMed · Cited by 526
Functional assessment scales: a study of persons with multiple sclerosis.
Cv, G., Ac, C., Bb, H., Fiedler, R., & Hens, M. M. (1990) · PubMed · Cited by 385
Vercoulen, J. H. M. M. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550070080014 · Cited by 383
Krupp, L. B., Coyle, P. K., Doscher, C., Miller, A., Cross, A. H., Jandorf, L., Halper, J., Johnson, B., Morgante, L., & Grimson, R. (1995) · Neurology · doi:10.1212/wnl.45.11.1956 · Cited by 359
Quality of Life Among Persons with Multiple Sclerosis and their Caregivers
Aronson, K. J. (1997) · Neurology · doi:10.1212/wnl.48.1.74 · Cited by 342
The Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis
Consroe, P., Musty, R., Rein, J., Tillery, W., & Pertwee, R. (1997) · European Neurology · doi:10.1159/000112901 · Cited by 323
The n-of-1 Randomized Controlled Trial: Clinical Usefulness: Our Three-Year Experience
Guyatt, G. H., Keller, J. L., Jaeschke, R., Rosenbloom, D., Adachi, J. D., & Newhouse, M. T. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-4-293 · Cited by 320
A clinician's guide for conducting randomized trials in individual patients.
Guyatt, G. H., Sackett, D. L., Adachi, J. D., Roberts, R. E., Chong, J. P., Rosenbloom, D., & Keller, J. (1988) · Europe PMC (PubMed Central) · Cited by 275
Neuropsychological Aspects of Multiple Sclerosis
Brassington, J. C., & Marsh, N. V. (1998) · Neuropsychology Review · doi:10.1023/a:1025621700003 · Cited by 258
Komaroff, A. L., Fagioli, L. R., Doolittle, T. H., Gandek, B., Gleit, M. A., Guerriero, R. T., Kornish, R. J., Ware, N. C., Ware, J. E., & Bates, D. W. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00174-x · Cited by 254
Rudick, R. A. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530360035014 · Cited by 246
A comprehensive assessment of the cost of multiple sclerosis in the United States
Whetten-Goldstein, K., Sloan, F. A., Goldstein, L. B., & Kulas, E. D. (1998) · Multiple Sclerosis Journal · doi:10.1177/135245859800400504 · Cited by 230
The Epidemiology of Multiple Sclerosis
Hogancamp, W. E., Rodriguez, M., & Weinshenker, B. G. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.9.871 · Cited by 225
Psychosocial correlates of fatigue in multiple sclerosis
Schwartz, C. E., Coulthard-Morris, L., & Zeng, Q. (1996) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(96)90162-8 · Cited by 216
Amantadine Therapy for Fatigue in Multiple Sclerosis
Murray, T. J. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100047107 · Cited by 212
Amantadine Treatment of Fatigue Associated With Multiple Sclerosis
Cohen, R. A., & Fisher, M. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520420096030 · Cited by 205
The nature of fatigue in multiple sclerosis
Ford, H., Trigwell, P., & Johnson, M. (1998) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(98)00004-x · Cited by 184
Cross-Over Trials in Clinical Research
Ziegel, E. R., & Senn, S. (1994) · Technometrics · doi:10.2307/1270263 · Cited by 177
Weinshenker, B. G., Penman, M., Bass, B., Ebers, G. C., & Rice, G. P. (1992) · Neurology · doi:10.1212/wnl.42.8.1468 · Cited by 155
Fatigue in MS is associated with specific clinical features
Colosimo, C., Millefiorini, E., Grasso, M. G., Vinci, F., Fiorelli, M., Koudriavtseva, T., & Pozzilli, C. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1995.tb00145.x · Cited by 152
A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis
The Canadian MS Research Group (1987) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100026603 · Cited by 150
The Effects of Amantadine and Pemoline on Cognitive Functioning in Multiple Sclerosis
Geisler, M. W., Sliwinski, M. J., Coyle, P. K., Masur, D. M., Doscher, C., & Krupp, L. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550020101021 · Cited by 144
Fabio, R. A., Soderberg, J., Choi, T., Hansen, C. R., & Schapiro, R. T. (1998) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(98)90290-8 · Cited by 136
Burden of Illness of Multiple Sclerosis: Part I: Cost of Illness
The Canadian Burden of Illness Study Group (1998) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100033448 · Cited by 130
NEUROPSYCHOLOGICAL ASPECTS OF MULTIPLE SCLEROSIS
Beatty, P. A., & Gange, J. J. (1977) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197701000-00008 · Cited by 125
4-Aminopyridine in the Treatment of Patients With Multiple Sclerosis
Polman, C. H. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540150090022 · Cited by 121
Quality of life in multiple sclerosis in France, Germany, and the United Kingdom
Murphy, N., Confavreux, C., Haas, J., Konig, N., Roullet, E., Sailer, M., Swash, M., Young, C., & J-L, M. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.4.460 · Cited by 119
The fatigue descriptive scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis
Iriarte, J., Katsamakis, G., & Castro, P. D. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500103 · Cited by 116
Clinical aspects of fatigue in multiple sclerosis.
Bergamaschi, R., Romani, A., Versino, M., Poli, R., & Cosi, V. E. (1997) · PubMed · Cited by 114
A multidimensional assessment of multiple sclerosis: relationships between disability domains
Provinciali, L., Ceravolo, M. G., Bartolini, M., Logullo, F. O., & Danni, M. C. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1999.tb00731.x · Cited by 95
Sheean, G. L. (1998) · Brain · doi:10.1093/brain/121.5.967 · Cited by 92
Amantadine, Fatigue, and Multiple Sclerosis
Rosenberg, G. A., & Appenzeller, O. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520340058012 · Cited by 84
Packer, T. L., Sauriol, A., & Brouwer, B. J. (1994) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/0003-9993(94)90088-4 · Cited by 80
Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients
Bever, C. T., Anderson, P. A., Leslie, J. L., PANITCH, H. S., Dhib-Jalbut, S. S., Khan, O., Milo, R., Hebel, J. R., Conway, K. L., Katz, E., et al. (1996) · Neurology · doi:10.1212/wnl.47.6.1457 · Cited by 76
Survey of multiple sclerosis in Northern California
Goodin, D. S., & Northern California MS Study Group (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500203 · Cited by 71
Endurance Training in Patients With Multiple Sclerosis: Five Case Studies
Svensson, B., Gerdle, B. U. C., & Elert, J. (1994) · Physical Therapy · doi:10.1093/ptj/74.11.1017 · Cited by 69
Carton, H., Loos, R. J. F., Pacolet, J., Versieck, K., & VLIETINCK, R. F. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.4.444 · Cited by 67
Polman, C. H., Bertelsmann, F. W., de Waal, R., van Diemen, H. A. M., Uitdehaag, B. M. J., Loenen, A. C. V., & Koetsier, J. C. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540230074016 · Cited by 58
Midgard, R., R�se, T., & Nyland, H. (1996) · Journal of Neurology · doi:10.1007/bf00868408 · Cited by 47
Bhise, V. V., Charvet, L. E., & Krupp, L. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780199341016.003.0020 · Cited by 46
Multiple Sclerosis: Symptomatic Therapies
Metz, L. M. (1998) · Seminars in Neurology · doi:10.1055/s-2008-1040888 · Cited by 30
Current pharmacologic treatment of multiple sclerosis symptoms.
Andersson, P.-B., & Goodkin, D. E. (1996) · Europe PMC (PubMed Central) · Cited by 26
Update on multiple sclerosis therapy
Mitchell, G. W. (1993) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30281-4 · Cited by 25
Management of Impairment, Disability, and Handicap Due to Multiple Sclerosis
Stolp‐Smith, K. A., Carter, J. L., Rohe, D. E., & Knowland, D. P. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.12.1184 · Cited by 23
Clinical Trials of Multiple Sclerosis
Hobart, J. C., & Thompson, A. J. (1997) · CRC Press eBooks · doi:10.1201/9781482273557-24 · Cited by 19
The n-of-1 Randomized Controlled Trial: Clinical Usefulness
Guyatt, G. H., Keller, J. L., Jaeschke, R., Rosenbloom, D., Adachi, J. D., & Newhouse, M. T. (2020) · Annals of Internal Medicine · Cited by 16
[Fatigue and functional system involvement in multiple sclerosis].
Iriarte, J., Carreño, M., & de Castro, P. (1996) · PubMed · Cited by 14
Choosing Drug Therapy for Multiple Sclerosis: An Update
van Oosten, B. W., Truyen, L., Barkhof, F., & Polman, C. H. (1998) · Drugs · doi:10.2165/00003495-199856040-00004 · Cited by 12
Cited by
Fatigue in neurological disorders
Chaudhuri, A., & Behan, P. O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15794-2 · Cited by 1,297
Validation of the Fatigue Severity Scale in a Swiss Cohort
Valko, P. O., Bassetti, C. L., Bloch, K. E., Held, U., & Baumann, C. R. (2008) · Sleep · doi:10.1093/sleep/31.11.1601 · Cited by 681
Flachenecker, P., Kümpfel, T., Kallmann, B., Gottschalk, M., Grauer, O., Rieckmann, P., Trenkwalder, C., & Toyka, K. V. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms839oa · Cited by 634
Hobart, J., & Cano, S. (2009) · Health Technology Assessment · doi:10.3310/hta13120 · Cited by 621
Randomized controlled trial of yoga and exercise in multiple sclerosis
Oken, B. S., Kishiyama, S., Zajdel, D., Bourdette, D., Carlsen, J., Haas, M., Hugos, C., Kraemer, D. F., Lawrence, J., & Mass, M. (2004) · Neurology · doi:10.1212/01.wnl.0000129534.88602.5c · Cited by 593
Metadata
- Authors
- Brañas, Jordan, Fry-Smith, Burls, & Hyde
- Venue
- Health Technology Assessment
- Published
- 2000
- Volume
- 4
- Issue
- 27
- Pages
- 1-61
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W1488603340
- Cited by
- 330
- References
- 59
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- Health Technology Assessment Programme (99/05/05)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.